Mammary Cell News

Mammary Cell News is an online resource covering the latest research into breast cancer and mammary cells.

The PML1-WDR5 Axis Regulates H3K4me3 Marks and Promotes Stemness of Estrogen Receptor-Positive Breast Cancer

April 16, 2024

[Cell Death & Differentiation] The authors discovered that PML1 is the most abundant isoform in all breast cancer subtypes, and its expression is associated with unfavorable prognosis in estrogen receptor-positive breast cancers.

Overcoming BRAF and CDK4/6 Inhibitor Resistance by Inhibiting MAP3K3-Dependent Protection Against YAP Lysosomal Degradation

April 16, 2024

[Experimental & Molecular Medicine] Researchers identified MAP3K3 as a target for overcoming anticancer drug resistance. Depletion of MAP3K3 led to a substantial reduction in the yes-associated protein (YAP) protein level in melanoma and breast cancer cells.

Atossa Therapeutics and Quantum Leap Healthcare Announce I-SPY 2 Clinical Trial To Evaluate (Z)-Endoxifen in Combination With Abemaciclib (VERZENIO®) in Women With ER+/HER2- Breast...

April 16, 2024

[Atossa Therapeutics, Inc.] Atossa Therapeutics, Inc. and Quantum Leap Healthcare Collaborative™ announced the initiation of a new study to evaluate Atossa’s (Z)-endoxifen in combination with abemaciclib, a cyclin-dependent kinase inhibitor marketed by Eli Lilly and Company, in women with ER+/HER2- breast cancer.

A Glycolytic Metabolite Bypasses “Two-Hit” Tumor Suppression by BRCA2

April 15, 2024

[Cell] The authors reported that the glycolytic metabolite methylglyoxal transiently bypasses Knudson’s paradigm by inactivating the breast cancer suppressor protein BRCA2 to elicit a cancer-associated, mutational single-base substitution signature in nonmalignant mammary cells or patient-derived organoids.

COL5A1 Promotes Triple-Negative Breast Cancer Progression by Activating Tumor Cell-Macrophage Crosstalk

April 12, 2024

[Oncogene] Scientists reported that upregulation of collagen type V alpha 1 (COL5A1) in TNBC tissues, particularly in chemoresistant samples, was closely linked to an unfavorable prognosis.

RUVBL1 Ubiquitination by DTL Promotes RUVBL1/2-β-Catenin-Mediated Transcriptional Regulation of NHEJ Pathway and Enhances Radiation Resistance in Breast Cancer

April 12, 2024

[Cell Death & Disease] Investigators revealed that RUVBL1 was excessively expressed in mouse models undergoing radiotherapy, which is considered a murine spontaneous breast-tumor model. RUVBL1 enhanced DNA damage repair and radioresistance in breast cancer cells both in vitro and in vivo.

Neratinib Could Be Effective As Monotherapy or in Combination With Trastuzumab in HER2-Low Breast Cancer Cells and Organoid Models

April 11, 2024

[British Journal Of Cancer] The authors investigated the effect of trastuzumab monotherapy and its combination with different HER2 targeting treatments in a panel of breast cancer cell lines and patient-derived organoids using biochemical methods and cell viability assays.

Sprouty Genes Regulate Activated Fibroblasts in Mammary Epithelial Development and Breast Cancer

April 10, 2024

[Cell Death & Disease] Investigators showed in mammary stromal fibroblasts that loss of the receptor tyrosine kinase (RTK) negative feedback regulators encoded by Spry1, Spry2, and Spry4 causes upregulation of signaling in multiple RTK pathways and increased extracellular matrix remodeling, resulting in accelerated epithelial branching.

Recent Developments in Targeting Breast Cancer Stem Cells (BCSCs): A Descriptive Review of Therapeutic Strategies and Emerging Therapies

April 10, 2024

[Medical Oncology] The authors summarize evolving strategies to target BCSCs, which have become a pivotal aspect of therapeutic development. They explore a variety of approaches, including targeting specific tumor surface markers, transporters, heat shock proteins, and critical signaling pathways like Notch, Akt, Hedgehog, KLF4, and Wnt/β-catenin.

Roche Obtains CE Mark for First Companion Diagnostic To Identify Patients with HER2-Low Metastatic Breast Cancer Eligible for ENHERTU

April 10, 2024

[F. Hoffmann-La Roche AG (BioSpace)] Roche announced the approval of the CE Mark for the VENTANA® HER2 Rabbit Monoclonal Primary Antibody RxDx* to identify metastatic breast cancer patients with low HER2 expression for whom ENHERTU® may be considered as a targeted treatment.

Texas A&M, University of Colorado Research Collaboration Wins Federal Grant To Help Turn Off ‘Breast Cancer Switch’

April 10, 2024

[Texas A&M University] Researchers at the Texas A&M School of Veterinary Medicine & Biomedical Sciences and the University of Colorado Cancer Center have received a $3.3 million grant from the National Institutes of Health to study how a pair of molecules that regulate certain types of metastatic breast cancer interact with a new drug therapy.

Selective Impact of ALK and MELK Inhibition on ERα Stability and Cell Proliferation in Cell Lines Representing Distinct Molecular Phenotypes of Breast Cancer

April 10, 2024

[Scientific Reports] Using classical signal transduction and cell proliferation methods, along with multiple breast cancer cell lines, scientists identified enhanced sensitivity of ERα-positive breast cancer cell lines to anaplastic lymphoma kinase (ALK) and maternal embryonic leucine zipper kinase (MELK) inhibitors, inducing ERα degradation and diminishing proliferation in specific breast cancer subtypes.

For over a decade, Mammary Cell News has been keeping the global scientific and medical communities informed about the latest research, reviews, and news in the field of mammary tissues. Our editors gather publications on the topic of mammary cell differentiation and characterization, as well as the progression and treatment of breast cancer. We also keep scientists up-to-date on the latest policy changes, job postings, and events.